ReviewInternational journal of molecular sciences2023
Current Treatments for Diabetic Macular Edema.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Efficacy of different routes of triamcinolone acetonide administration on macular edema: A systematic review and network meta-analysis.PloS one · 2025Pooled it
- Application of continuous care based on IKAP theory in patients with diabetic macular edema.Scientific reports · 2026Trial
- Article
- Early diabetes impairs visual function in mice through altering neuronal activity in the primary visual cortex.IBRO neuroscience reports · 2026Article
- Immediate versus delayed dexamethasone implantation during vitrectomy for diabetic macular edema with secondary epiretinal membrane: A retrospective comparative study.The Journal of international medical research · 2026Article
- Short-term intraocular pressure changes following intravitreal aflibercept 8 mg versus 2 mg in diabetic macular edema: a prospective observational study.Scientific reports · 2026Observational
- Synergistic inhibition of macular vascular permeability in diabetic edema: Ginsenoside Rg3 enhances ranibizumab efficacy by targeting angiopoietin-like protein 4 and vascular endothelial growth factor via neuropilin/RhoA signaling.Journal of diabetes investigation · 2026Article
- Endothelial UNC5B regulates blood‑retinal barrier homeostasis.International journal of molecular medicine · 2026Article
- Development of a predictive model based on aqueous cytokines data for response to anti-VEGF therapy in diabetic macular edema.Eye and vision (London, England) · 2026Article
- Comparative evaluation of stability, efficacy, and sterility in five repackaged intravitreal anti-vascular endothelial growth factor medications.Scientific reports · 2026Article
- Impact of baseline visual acuity, time-in-range and early treatment on functional outcomes in DMO: insights from the IRISS outcomes.Eye (London, England) · 2026Article
- Quantifying the direct costs of diabetic retinopathy in a mixed healthcare system: a hospital-based study from governmental and patient perspectives.Cost effectiveness and resource allocation : C/E · 2026Article
- Changes in retinal venous diameter in proliferative diabetic retinopathy patients with diabetic macular edema following faricimab treatment: an observational study.Frontiers in endocrinology · 2026Observational
- Elevated carbonic anhydrase-1 in the aqueous humor in diabetic macular edema: associations between inflammatory cytokines and retinal vascular dysfunction.Frontiers in medicine · 2026Article
- Comparison of Patients with Diabetic Macular Edema Undergoing Early versus Late Switch from Intravitreal Anti-VEGF Therapy to Dexamethasone Implant.Beyoglu eye journal · 2026Article
- Patient and Physician Perspectives on the Management of Diabetic Macular Edema.Ophthalmology and therapy · 2026Article
- Efficacy of Avastin in Improving Visual Acuity and Reducing Retinal Swelling in Patients with Diabetic Retinopathy at a Hospital in Gauteng (SA).Clinical optometry · 2026Article
- Characteristics of striatal changes in diabetic retinopathy and type 2 diabetes: a resting-state functional magnetic resonance imaging study.Frontiers in human neuroscience · 2026Article
- Endothelial mitochondrial-derived vesicles (EMDVs) with retinal targeted homing properties dynamically modulate the eIF2α-ATF4-CHOP signaling pathway and efficiently restore mitochondrial homeostasis in diabetic retina.Journal of nanobiotechnology · 2025Article
- Blood Cell-Derived Inflammatory Indices in Diabetic Macular Edema: Clinical Significance and Prognostic Relevance.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy is a major retinal disorder and a leading cause of blindness. Diabetic macular edema (DME) is an ocular complication in patients with diabetes, and it can impair vision significantly. DME is a disorder of the neurovascular system, and it causes obstructions of the retinal capillaries, damage of the blood vessels, and hyperpermeability due to the expression and action of vascular endothelial growth factor (VEGF). These changes result in hemorrhages and leakages of the serous components of blood that result in failures of the neurovascular units (NVUs). Persistent edema of the retina around the macula causes damage to the neural cells that constitute the NVUs resulting in diabetic neuropathy of the retina and a reduction in vision quality. The macular edema and NVU disorders can be monitored by optical coherence tomography (OCT). Neuronal cell death and axonal degeneration are irreversible, and their development can result in permanent visual loss. Treating the edema before these changes are detected in the OCT images is necessary for neuroprotection and maintenance of good vision. This review describes the effective treatments for the macular edema that are therefore neuroprotective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.